Olive Leaf Report Documents Promising Therapeutic Interventions for 9-11 Workers
Treatment for High Levels of Mercury and Lead Toxicity In Ground Zero Rescue and Recovery Workers and Lower Manhattan Residents
Philadelphia, October 24, 2006 — In a Special Report published in the September/October issue of EXPLORE: The Journal of Science and Healing, Claire Haaga Altman, President and Dr. Kamau Kokayi, MD, Medical Director of the Olive Leaf Wholeness Center in New York City outlined the program used to treat 160 uniformed service personnel and residents of Lower Manhattan who were exposed to the air at Ground Zero during the 9-11 attacks.
More than 2400 chemicals and metals were combusted when the twin towers collapsed. The major ones identified as being potentially toxic to humans were: asbestos, lead, mercury, dioxins and furans, diesel fuels and oils, benzenes and other volatile organic compounds. Project Olive ReLeaf found most individuals who were exposed had 8 or more serious health complaints including: severe respiratory problems, digestive problems, skin rashes, sleeplessness, anxiety, depression, weight gains and elevated blood pressure, lethargy, and recurrent headaches.
This is consistent with the findings of the recent Mt Sinai Study, which unveiled that roughly 70 percent of nearly 10,000 workers who were tested from 2002 to 2004 had new or substantially worsened respiratory problems while or after working at ground. (This study was recently published in Environmental Health Perspectives, the journal of the National Institute of Environmental Health Sciences.) In addition, a recent study by the New York City Fire Department found that on average firefighters who worked at Ground Zero have lost up to 12 years of lung capacity as a result of their exposure to the toxins at the site.
The Olive ReLeaf team had suspected since 2002 that heavy metal toxicity might be a causal factor for many of the symptoms the rescue workers and Lower Manhattan residents were reporting. A challenge urine test was administered to measure heavy metal toxicity. Eighty-five percent (85%) of those tested had excessively high levels of lead and mercury in their systems.
A key component of the treatment in the Olive Releaf program were given Chelation therapy using DMSA (Dimercaptuosuccinic acid), an FDA approved sulfur compound. In addition, adjunctive therapies to assist with the detoxification process and build the immune system were offered including, acupuncture, bioenergetic neuromodulation, Chinese herbal medicine, antioxidants, intravenous glutathione, and supplementation with NAC, glutathione, alpha lipoic acid and Vitamin C.
After 3-4 months of treatment, the first cohort of 100 reported significant (greater than 60%) improvement in all symptoms.
# # #
EXPLORE: The Journal of Science and Healing addresses the scientific principles behind, and applications of, evidence-based healing practices from a wide variety of sources, including conventional, alternative, and cross-cultural medicine. It is an interdisciplinary journal that explores the healing arts, consciousness, spirituality, eco-environmental issues, and basic science as all these fields relate to health.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.Media Contact
Tel: +1 215 239 3654